| Title |
Two acute psychotic episodes after administration of bupropion: a case of involuntary rechallenge
|
|---|---|
| Published in |
International Journal of Clinical Pharmacy, November 2008
|
| DOI | 10.1007/s11096-008-9272-x |
| Pubmed ID | |
| Authors |
Hervé Javelot, Alexandre Baratta, Luisa Weiner, Thierry Javelot, Cathy Nonnenmacher, Jean-Frédéric Westphal, Michaël Messaoudi |
| Abstract |
Bupropion is an antidepressant drug also used as a smoking cessation aid, which inhibits norepinephrine and dopamine re-uptake. Given its pharmacological properties, it has been associated with reports on psychosis and acute delirious episodes. Case We report the case of a patient with schizoaffective disorder who developed two psychotic episodes respectively after a four and a two-day administration of sustained-release (SR) bupropion at a dose of 150 mg/day. To our knowledge, this is the first reported case of involuntary rechallenge with bupropion SR during a smoking cessation program. Conclusion There is a serious risk of incorrectly identifying bupropion as only a therapy for nicotine withdrawal without taking the precaution of exploring possible psychiatric co-morbidity with addiction. Our case illustrates the problem. |
Mendeley readers
The data shown below were compiled from readership statistics for 23 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 23 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 5 | 22% |
| Student > Ph. D. Student | 3 | 13% |
| Student > Doctoral Student | 3 | 13% |
| Student > Master | 3 | 13% |
| Researcher | 2 | 9% |
| Other | 1 | 4% |
| Unknown | 6 | 26% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 6 | 26% |
| Psychology | 4 | 17% |
| Agricultural and Biological Sciences | 2 | 9% |
| Social Sciences | 2 | 9% |
| Unspecified | 1 | 4% |
| Other | 3 | 13% |
| Unknown | 5 | 22% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 January 2011.
All research outputs
#8,535,472
of 25,374,917 outputs
Outputs from International Journal of Clinical Pharmacy
#632
of 1,579 outputs
Outputs of similar age
#51,558
of 179,379 outputs
Outputs of similar age from International Journal of Clinical Pharmacy
#2
of 5 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. This one is in the 43rd percentile – i.e., 43% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,579 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.5. This one is in the 41st percentile – i.e., 41% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 179,379 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 18th percentile – i.e., 18% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 5 others from the same source and published within six weeks on either side of this one. This one has scored higher than 3 of them.